Abstracts from 2014 through the most recent CROI can be viewed in this searchable database once they have been presented at the conference. Abstract Contents: The searchable database includes abstract text as submitted by the authors prior to CROI. Study data might be updated during the presentation at CROI. Please refer to the electronic poster or webcast for updates. Searching the Abstract Database: Enter the criteria below and click the “Search” button. After the search has been entered, the results will appear below the search form.
CROI conference materials (eg, the conference program, Abstract eBook, electronic posters, CROI logo, etc) are protected by copyright. Permission to replicate or reproduce these elements, in whole or in part, must be obtained from the CROI Conference Manager, the International Antiviral Society-USA (IAS-USA). Study data (including figures within abstracts or electronic posters) are the property of the study authors. Permission to use data and figures cannot be given by IAS–USA unless it is for regulatory reasons. For more information, please email CROIabstracts@iasusa.org.
1277 Results
Background HIV is an established risk factor for coronary atherosclerotic disease (CAD) in the United States and Europe. However, data linking HIV infection with coronary atherosclerosis in the African region are lacking. Methods We enrolled people living with HIV (PWH) over 40 and on antiretroviral therapy (ART) for a minimum of three years from public-sector…
Background Cardiovascular disease (CVD) risk is higher in people with HIV (PWH) than people without HIV. However, whether this elevated risk of CVD is present in antiretroviral therapy (ART)-naïve PWH with high CD4+ counts, and whether delayed initiation of ART worsens CVD outcomes is unknown. Methods The Strategic Timing of Antiretroviral Treatment (START) study randomized…
Background People with HIV (PWH) are at increased risk for atherosclerotic cardiovascular diseases (ASCVD) and accelerated aging, including frailty. REPRIEVE demonstrated a 36% reduction in the hazard of major adverse cardiovascular events (MACE) for pitavastatin vs placebo among PWH, but little is known about statins for ASCVD prevention among PWH with frailty. The goal of…
Background Epigenetic age acceleration has prognostic value in the general population. However, its role in predicting clinical outcomes in people with HIV (PWH) with long-term virological suppression remains unclear Methods Retrospective cohort of PWH with long-term virological suppression, followed at a single HIV unit. Blood DNA methylation was assessed using the Illumina Infinium MethylationEPIC BeadChip,…
Background Antiretroviral therapy (ART) has transformed HIV from a life-threatening infection into a manageable chronic condition, allowing people living with HIV (PLWH) to have a significantly longer lifespan. However, as this population ages, they become increasingly susceptible to non-AIDS-related comorbidities typically associated with aging. Understanding the evolving patterns of these age-related conditions is essential to…
Background The rapid emergence of immune-evasive SARS-CoV-2 variants poses a significant challenge, as current therapies and vaccines struggle to keep pace. SNS812, an aerosolized broad-spectrum antiviral siRNA, targets a conserved region of the RNA-dependent RNA polymerase gene, unchanged since the 2003 SARS outbreak, offering potential efficacy against diverse variants. In a 2023 Phase I trial (NCT05677893)…
Background Tissue resident memory T cells (TRMs) protect the gut mucosal barrier against microbial invasion by exerting rapid and localized effector functions while restraining excessive inflammation. Yet, pathogens can evade immune clearance and persist. The gut is a major HIV-1 reservoir in people living with HIV-1 (PLWH). However, given the rarity of HIV-1-infected cells (<0.1%) and the…
Background People living with HIV (PLWH) receiving HIV integrase (IN) strand transfer inhibitors (INSTIs) have been reported to experience virological failure (VF) in the absence of resistance mutations in IN. To elucidate INSTI resistance mechanisms and pathways, we performed long-term (~ one year) passaging of several viral isolates with an escalating concentration of the INSTI…
Background Neurologic consequences of HIV linger even after viral suppression, suggesting a molecular “scar” that persists despite antiretroviral therapy (ART). However, whether innate immune cells in the cerebrospinal fluid (CSF) are altered during HIV and how they contribute to neuropathogenesis are poorly understood, owing in part to difficulties in isolating these rare populations of cells…
Background Tenofovir-lamuvidine-dolutegravir (TLD) is highly effective as ART but the causes of virologic failure (VF) in individuals on TLD without integrase (IN) resistance mutations are not well understood. Off-target mutations in nucleocapsid (NC) have been selected in vitro and are associated with decreased DTG susceptibility in vitro. Samples from ACTG study A5381 were examined to…